KUALA LUMPUR: CIMB Equities Research has started coverage of Hovid with an Outperform call and a target price of 43 sen, based on sum-of-parts valuation.
It said on Wednesday the re-rating catalysts could come from increased product registrations in its export markets and strong earnings growth.
Already a subscriber? Log in.
Celebrate Merdeka with 50% Off!
T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
